A new drug to treat an aggressive form of breast cancer which was trialled at the Christie in Manchester has been given approval.
The results of the trials show Perjeta can extend the lives of patients by 6 months and can stop the disease getting worse.
Consultant at The Christie, Dr Andrew Wardley said "Today's approval of Perjeta marks a major advance in the fight against HER2-positive breast cancer.
To find a treatment that not only controls cancer for longer than the current gold standard but also extends the lives of patients is a rare achievement and something that we haven't seen since the launch of Herceptin more than ten years ago.
"If Perjeta is funded, this will be welcome news for patients living with this aggressive disease throughout the North West."
It's hoped the drug will be made available on the NHS but in the meantime the pharmaceutical company Roche says patients should be able to access Perjeta via the Cancer Drugs Fund.
Patients being treated for breast cancer at an Isle of Man hospital are having their treatment reviewed.
Doctors say there is nothing wrong with their diagnosis but they need to attend a clinic after an issue arose with tissue tests that were used to decided "appropriate additional treatment".
The Noble Hospital has identified 22 patients who are affected. They are being contacted directly and being asked to attend a clinic appointment to discuss their treatment. More patients could be contacted as the review continues.
"Caring for patients is our priority and we appreciate that some patients and their families will be concerned by the fact that their current treatment may need to be reviewed.
"Noble’s Hospital is acting on the basis of information as it becomes available and all affected patients will be seen as quickly as possible."
– Stephen Upsdell, Noble Hospital medical director
Patients who are concerned 651300 between 9am and 6pm and speak to the Breast Care team.
Women who've been treated for Hodgkins Lymphoma are five times more likely to go on to develop breast cancer. The findings were made after a landmark study carried out by the Institute of Cancer Research, over the last 50 years.
Doctors at the Christie in Manchester hope the results can now be used to help protect those women who are most vulnerable. Our correspondent Rachel Townsend reports